FDA Considers Expanding Testosterone Therapy Use for Low Sex Drive in Men
The U.S. Food and Drug Administration is evaluating a proposal to broaden the use of testosterone replacement therapy to treat low sex drive in men with unexplained low hormone levels.
Currently, testosterone therapy is approved only for men whose low testosterone is linked to identifiable structural or genetic causes. The proposed expansion would extend eligibility to those diagnosed with idiopathic hypogonadism, a condition where the body produces insufficient testosterone without a clearly defined underlying cause.
Potential Shift in Treatment Scope
The FDA’s consideration follows emerging clinical evidence suggesting that testosterone therapy could improve symptoms that significantly impact quality of life, including reduced libido.
Marty Makary noted that early research findings appear promising, prompting the agency to invite pharmaceutical companies to submit applications for expanded indications by April 30.
Balancing Benefits and Risks
The regulator emphasized that any approval would depend on rigorous scientific validation and a thorough assessment of safety risks versus therapeutic benefits. Testosterone therapy has historically been scrutinized for potential side effects, including cardiovascular risks and hormone-related complications.
The FDA previously convened an expert panel in December 2025 to evaluate the clinical and safety implications of expanding access to the therapy, highlighting the complexity of the decision.
Industry and Patient Impact
If approved, the move could significantly expand the addressable patient population for testosterone treatments, offering new options for men experiencing symptoms that affect daily functioning and well-being.
At the same time, the decision underscores the FDA’s cautious approach to broadening treatment indications—ensuring that expanded access is supported by strong evidence and aligned with patient safety priorities.
The outcome of the review could reshape how low testosterone is diagnosed and managed, particularly for patients whose symptoms currently fall outside existing treatment guidelines.
